August 24, 2010
Ferumoxytol PK Model Published
Results of a population pharmacokinetic analysis of ferumoxytol were published in the August 2010 issue of Clinical Pharmacology and Therapeutics. A 2-compartment open model with 0-order input and Michaelis–Menten elimination best described the data from a study of 58 healthy volunteers who received ferumoxytol in two 510-mg doses administered 24 h apart. The population mean estimates for volume of distribution of the central compartment (V1), maximal elimination rate, and ferumoxytol concentration at which the rate of metabolism would be one-half of Vmax were 2.71 L, 14.3 mg/h, and 77.5 mg/L, respectively. When the effect of body weight on V1 was added in the analysis, interindividual variability was found to be reduced. Ferumoxytol (Feraheme) is a novel IV iron formulation for treatment of iron-deficiency anemia in patients with chronic kidney disease. The study was sponsored by AMAG Pharmaceuticals in collaboration with Cognigen Corporation and the Albany Nephrology Pharmacy Group.
Pai AB, Nielsen JC, Kausz A, Miller P, Owen JS. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects. Clin Pharmacol Ther. 2010:88(2):237–242. doi:10.1038/clpt.2010.80.